Download PDF
Exp Clin Endocrinol Diabetes 2010; 118(9): 633-637
DOI: 10.1055/s-0029-1237705
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

The Effect of Metformin Treatment for 2 Years without Caloric Restriction on Endocrine and Metabolic Parameters in Women with Polycystic Ovary Syndrome

P. G. Oppelt[*] 1 , A. Mueller[*] 1 , K. Jentsch1 , D. Kronawitter1 , C. Reissmann1 , R. Dittrich1 , M. W. Beckmann1 , S. Cupisti1
  • 1Department of Obstetrics and Gynecology, University Hospital Erlangen, Germany
Further Information

Publication History

received 19.05.2009 first decision 08.06.2009

accepted 30.07.2009

Publication Date:
08 December 2009 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: The aim of this study was to evaluate long-term changes in endocrine and metabolic parameters and body mass index in women with polycystic ovary syndrome (PCOS) who were treated with metformin over 2 years without caloric restriction.

Material and Methods: Twenty-six obese women with PCOS were treated with metformin over 2 years without caloric restriction. Clinical, metabolic and endocrine parameters and the body mass index were measured and an oral glucose tolerance test was carried out to calculate insulin resistance indices at the beginning and at the follow-up after 2 years. The Homeostatic Model for Assessment of Insulin Resistance (HOMA-IR) was calculated.

Results: No significant changes in body mass index or HOMA-IR were observed. However, a significant decrease in fasting and 2-h insulin levels was observed. Women showed a significant increase in sex hormone–binding globulin (SHBG) levels, while total testosterone (TT) levels and the free androgen index decreased significantly. Furthermore a significant decrease in Hirsutism was observed. There was a decrease in cholesterol and an increase in high-density lipoprotein.

Conclusions: Long-term treatment with metformin in women with PCOS appears to reduce androgen excess due to increased SHBG and decreased TT levels resulting in improvement of Hirsutism as a clinical sign of androgen excess. Furthermore a significant decrease in fasting and 2-h insulin levels and slightly improved insulin resistance indices were observed.

Key words

insulin resistance - hyperandrogenemia - hormones - polycystic - ovary syndrome - obesity

References

  • 1 Alberti KG. The costs of non-insulin-dependent diabetes mellitus.  Diabetic Medicine. 1997;  14 7-9
    Google Scholar
  • 2 American Diabetes Association . Economic consequences of diabetes mellitus in the U.S. in 1997.  Diabetes Care. 1998;  21 296-309
    Google Scholar
  • 3 Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Practice & Research.  Clinical Obstetrics & Gynaecology. 2004;  18 737-754
    Google Scholar
  • 4 Azziz R, Carmina E, Dewailly D. et al. . Androgen Excess Society Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.  Journal of Clinical Endocrinology and Metabolism. 2006;  91 4237-4245
    Google Scholar
  • 5 Chen MJ, Yang WS, Yang JH. et al . Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS.  Human Reproduction. 2006;  21 2261-2271
    Google Scholar
  • 6 Cho LW, Kilpatrick ES, Keevil BG. et al . Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.  Clinical Endocrinology (Oxford). 2009;  70 233-237
    Google Scholar
  • 7 Cupisti S, Kajaia N, Dittrich R. et al . Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.  European Journal of Endocrinology. 2008;  158 711-719
    Google Scholar
  • 8 Dahlgren E, Johansson S, Lindstedt G. et al . Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.  Fertility and Sterility. 1992;  57 505-513
    Google Scholar
  • 9 De Leo V, Musacchino MC, Morgante G. et al . Metformin treatment is effective in obese teenage girls with PCOS.  Human Reproduction. 2006;  21 2252-2256
    Google Scholar
  • 10 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.  Endocrine Reviews. 1997;  18 774-800
    Google Scholar
  • 11 Ehrmann DA, Barnes RB, Rosenfield RL. et al . Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.  Diabetes Care. 1999;  22 141-146
    Google Scholar
  • 12 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.  Lancet. 2005;  365 1415-1428
    Google Scholar
  • 13 Fleming R, Hopkinson ZE, Wallace AM. et al . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.  Journal of Clinical Endocrinology and Metabolism. 2002;  87 569-574
    Google Scholar
  • 14 Guzick DS. Do cardiovascular risk factors in polycystic ovarian syndrome result in more cardiovascular events?.  Journal of Clinical Endocrinology and Metabolism. 2008;  93 1170-1171
    Google Scholar
  • 15 Hoeger K, Davidson K, Kochman L. et al . The impact of metformin, oral contraceptives and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials.  Journal of Clinical Endocrinology and Metabolism. 2008;  93 4299-4306
    Google Scholar
  • 16 Ibáñez L, López-Bermejo A, Díaz M. et al . Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche.  Journal of Clinical Endocrinology and Metabolism. 2008;  93 1841-1845
    Google Scholar
  • 17 Isomaa B, Almgren P, Tuomi T. et al . Cardiovascular morbidity and mortality associated with the metabolic syndrome.  Diabetes Care. 2001;  24 683-689
    Google Scholar
  • 18 Kajaia N, Binder H, Dittrich R. et al . Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome.  European Journal of Endocrinology. 2007;  157 499-507
    Google Scholar
  • 19 Katz A, Nambi SS, Mather K. et al . Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.  Journal of Clinical Endocrinology and Metabolism. 2000;  85 2402-2410
    Google Scholar
  • 20 Kocak M, Caliskan E, Simsir C. et al . Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.  Fertility and Sterility. 2002;  77 101-106
    Google Scholar
  • 21 Korytkowski MT, Krug EL, Daly MA. et al . Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes?.  Metabolism. 2005;  54 1626-1631
    Google Scholar
  • 22 Luque-Ramírez M, Alvarez-Blasco F, Uriol Rivera MG. et al . Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.  Human Reproduction. 2008;  23 1594-1601
    Google Scholar
  • 23 Maciel GA, Soares Junior JM, Alves da Motta EL. et al . Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.  Fertility and Sterility. 2004;  81 355-360
    Google Scholar
  • 24 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.  Diabetes Care. 1999;  22 1462-1470
    Google Scholar
  • 25 Matthews DR, Hosker JP, Rudenski AS. et al . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 26 Meigs JB, Rutter MK, Sullivan LM. et al . Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.  Diabetes Care. 2007;  30 1219-1225
    Google Scholar
  • 27 Moghetti P, Castello R, Negri C. et al . Metformin effects on clinical features, endocrine and metabolic profile, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-con-trolled 6-month trial, followed by open, long-term clinical evaluation.  Journal of Clinical Endocrinology and Metabolism. 2000;  85 139-146
    Google Scholar
  • 28 Morin-Papunen LC, Vauhkonen I, Koivunen RM. et al . Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.  Journal of Clinical Endocrinology and Metabolism. 2000;  85 3161-3168
    Google Scholar
  • 29 Nestler JE, Powers LP, Matt DW. et al . A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.  Journal of Clinical Endocrinology and Metabolism. 1991;  72 83-89
    Google Scholar
  • 30 Nestler JE. Metformin for the treatment of the polycystic ovary syndrome.  New England Journal of Medicine. 2008;  358 47-54
    Google Scholar
  • 31 Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial.  Human Reproduction. 2001;  16 1625-1631
    Google Scholar
  • 32 Norman RJ, Dewailly D, Legro RS. et al . Polycystic ovary syndrome.  Lancet. 2007;  370 685-697
    Google Scholar
  • 33 Pasquali R, Gambineri A, Biscotti D. et al . Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.  Journal of Clinical Endocrinology and Metabolism. 2000;  85 2767-2774
    Google Scholar
  • 34 Petra PH. The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function.  Journal of Steroid Biochemistry and Molecular Biology. 1991;  40 735-753
    Google Scholar
  • 35 Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.  Fertility and Sterility. 2002;  77 1095-1105
    Google Scholar
  • 36 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
    Google Scholar
  • 37 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.  Fertility and Sterility. 2004;  81 19-25
    Google Scholar
  • 38 Shaw LJ, Bairey Merz CN, Azziz R. et al . Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health – National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.  Journal of Clinical Endocrinology and Metabolism. 2008;  93 1276-1284
    Google Scholar
  • 39 Trolle B, Flyvbjerg A, Kesmodel U. et al . Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.  Human Reproduction. 2007;  22 2967-2973
    Google Scholar
  • 40 Velazquez EM, Mendoza S, Hamer T. et al . Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.  Metabolism. 1994;  43 647-654
    Google Scholar
  • 41 Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach.. In:, Dunaif A, Givens JR, Haseltine FP, &Merriam, Eds Polycystic Ovary Syndrome. GR. Boston: Blackwell Scientific; 1992: pp 377-384
    Google Scholar

1 Both authors contributed equally.

Correspondence

Dr. A. Mueller

Department of Obstetrics and Gynecology

Erlangen University Hospital

Universitätsstraße 21–23

D-91054 Erlangen

Germany

Phone: +49/9131/853 35 53

Fax: +49/9131/853 35 52

Email: andreas.mueller@uk-erlangen.de

      >